Rhoen Klinikum AG (RKAGY) fair value: what the stock is really worth
As of Sep 18, 2026: fair value of Rhoen Klinikum AG $8.65, price $8.16, upside +6.0%, quality 52 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Rhoen Klinikum AG ADR for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $5.17 – $17.94 · fair‑value band $6.49 – $10.83 · the $8.16 price screens below the $8.65 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Rhoen Klinikum AG ADR in your weekly email
Every Wednesday you see whether Rhoen Klinikum AG ADR is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
RHÖN-KLINIKUM, together with its subsidiaries, provides in-patient, semi-patient, and outpatient healthcare services in Germany. The company operates acute hospitals, medical care centers, and rehabilitation hospitals. RHÖN-KLINIKUM was founded in 1973 and is based in Bad Neustadt an der Saale, Germany.
Stock analysis
Rhoen Klinikum AG ADR (RKAGY) currently trades at $8.16, while our model-based Fair Value estimate is $8.65, implying the stock looks roughly 5.7% fairly valued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of $6.61 per share, and 0 of the 14 models we run sit above the $8.16 price.
Bear case: the Earnings-Based group reads lowest at $1.33, and 14 of the 14 models stay below the price. Evidence for this calculation is medium.
Scenario range: $6.49 (bear) to $10.83 (bull), the price of $8.16 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Rhoen Klinikum AG ADR reported revenue of €1.9B in FY2025 versus €1.6B in FY2021, a compound +4.0%/yr. Reported net income was €33.1M in FY2025, compounding +4.0%/yr from FY2021.
Key figures
Market cap $1.1B · P/E ratio 24.7 · P/S ratio 0.44 · EPS (TTM) $0.3300 · Dividend yield 2.5% · Net margin 1.8% · Return on equity 3.1% · Return on assets (EBIT) 1.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside, at 6%, RKAGY screens richer than that median.
Fair Value models
Bear $6.49Fair Value $8.65Bull $10.83
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.0951 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+16.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.5%
Start year 2020 (pandemic). Over 10 years: +5.3% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+5.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+3.2%
Dividend (yield on the price)2.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.3% vs −8%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.1% → 0%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 258 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score52 · Below median
Fair Value upside+6% · Above median
Profitability
Return on equity (TTM)3% · Below median
Return on assets2% · Below median
Net margin (TTM)2% · Below median
Operating margin (TTM)3% · Bottom 25%
Growth and dividend
Revenue growth7% · Above median
Dividend yield (TTM)2.5% · Above median
Balance sheet
Debt / equity0.01× · Lowest 25%
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Rhoen Klinikum AG ADR Fair Value". https://www.fairvalue-calculator.com/stock/RKAGY
Frequently asked questions
Is Rhoen Klinikum AG (RKAGY) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $8.65 versus a price of $8.16, about +6% upside (fairly valued).
What is the fair value of RKAGY?
Our model-based fair value for Rhoen Klinikum AG ADR is $8.65 (as of Sep 24, 2026), built from audited fundamentals. The current price: $8.16.
What is the quality score of RKAGY?
Rhoen Klinikum AG ADR has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Rhoen Klinikum AG (RKAGY)?
Our model-based price target is the fair value of $8.65 (as of Sep 24, 2026) from 14 valuation models. Cautious scenario $6.49, optimistic scenario $10.83. It is a calculation from audited fundamentals, not an analyst target.
What is the Rhoen Klinikum AG ADR stock forecast for 2026?
Our models put fair value at $8.65, about +6% upside versus a price of $8.16 (fairly valued). Cautious scenario $6.49, optimistic scenario $10.83. The calculation is refreshed regularly with new filings.
What is the revenue of Rhoen Klinikum AG (RKAGY)?
Rhoen Klinikum AG ADR reported trailing-twelve-month revenue of about $2.0B (latest available figure, as of Sep 24, 2026).
Does Rhoen Klinikum AG ADR pay a dividend?
Rhoen Klinikum AG ADR currently shows a dividend yield of about 2.45% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Rhoen Klinikum AG (RKAGY)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Rhoen Klinikum AG ADR it is $8.65 per share (as of Sep 24, 2026), against a price of $8.16. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Rhoen Klinikum AG ADR stock overvalued or undervalued in 2026?
As of Sep 24, 2026, RKAGY trades below its calculated fair value: price $8.16, fair value $8.65, a gap of about +6% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RKAGY?
No. The price is what the market pays today ($8.16); the fair value is what the company's own numbers justify ($8.65). For Rhoen Klinikum AG ADR the two are $0.4910 per share apart. That gap is exactly why we show both numbers side by side.
How much is Rhoen Klinikum AG ADR worth?
The market values Rhoen Klinikum AG ADR at about $1.1B (market capitalisation, as of Sep 24, 2026). Per share that is $8.16; our models calculate a fair value of $8.65 per share.
What do the bullish and bearish scenarios say about RKAGY?
Our models span a range for Rhoen Klinikum AG ADR: cautious scenario $6.49, base $8.65, optimistic $10.83 per share (as of Sep 24, 2026, price $8.16). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of RKAGY?
Rhoen Klinikum AG ADR trades at a price-to-earnings ratio of 24.7 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $8.65 is built from several models across several years. Other multiples: P/B 0.8, P/S 0.5, EV/EBITDA 8.7.
How solid is the balance sheet of Rhoen Klinikum AG (RKAGY)?
Balance-sheet figures for Rhoen Klinikum AG ADR (as of Sep 24, 2026): return on equity 3.1%, debt of 0.01 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
Which stocks are comparable to Rhoen Klinikum AG ADR?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Rhoen Klinikum AG ADR stock attractive at the current price?
The data as of Sep 24, 2026: price $8.16, calculated fair value $8.65 (+6%), Quality Score 52/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RKAGY calculated?
We run Rhoen Klinikum AG ADR through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $8.65, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Rhoen Klinikum AG ADR currently trades 6 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Rhoen Klinikum AG (RKAGY)?
The closing price on Sep 18, 2026 was $8.16. Our model-based fair value is $8.65, about +6% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Rhoen Klinikum AG ADR right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Where does the earnings growth of Rhoen Klinikum AG (RKAGY) come from?
Earnings per share at Rhoen Klinikum AG ADR grew −21.4 % a year from 2014 to 2025. Broken into its drivers: revenue per share +6.5 %, EBIT margin −28.8 %, tax rate −2.1 %, residual (interest, one-offs) +5.9 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Rhoen Klinikum AG ADR
How large is the market capitalisation of Rhoen Klinikum AG (RKAGY)?
The market capitalisation of Rhoen Klinikum AG ADR is $1.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Rhoen Klinikum AG (RKAGY)?
The price-to-sales ratio of Rhoen Klinikum AG ADR is 0.44 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Rhoen Klinikum AG (RKAGY)?
Earnings per share at Rhoen Klinikum AG ADR are $0.3300 (price ÷ EPS = P/E 24.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Rhoen Klinikum AG (RKAGY)?
The dividend yield of Rhoen Klinikum AG ADR is 2.5% (payout 60.6%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Rhoen Klinikum AG (RKAGY)?
The net margin of Rhoen Klinikum AG ADR is 1.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Rhoen Klinikum AG (RKAGY)?
The return on equity (ROE) of Rhoen Klinikum AG ADR is 3.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Rhoen Klinikum AG (RKAGY)?
On an EBIT basis the return on assets of Rhoen Klinikum AG ADR is 1.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Rhoen Klinikum AG (RKAGY)?
The operating margin of Rhoen Klinikum AG ADR is 3.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Rhoen Klinikum AG (RKAGY)?
Revenue at Rhoen Klinikum AG ADR is growing +6.8% versus a year earlier (3y avg +8.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Rhoen Klinikum AG (RKAGY)?
Earnings per share at Rhoen Klinikum AG ADR are growing +72.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Rhoen Klinikum AG (RKAGY) generate?
The free cash flow of Rhoen Klinikum AG ADR is −$33.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Rhoen Klinikum AG (RKAGY) hold?
Rhoen Klinikum AG ADR holds more cash than debt, $48.1M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Rhoen Klinikum AG ADR in the live analysis
One click puts Rhoen Klinikum AG ADR on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Some data
Sep 24, 2026